CryoPort, Inc. (CYRX)

Over the past six months, CryoPort's stock has been influenced by several key events. In Q1 2025, the company reported EPS that beat estimates but missed on sales, and revenue from continuing operations increased year-over-year. The company lowered its full-year 2025 sales outlook due to anticipated softness in demand for MVE Biological Solutions products. Cryoport completed the divestiture of CRYOPDP and commenced a strategic partnership with DHL Group. In Q2 2025, Cryoport reported a significant net loss but revenue from continuing operations rose, and the company announced a share repurchase program. Analyst ratings have varied, with some reiterating or upgrading to a "Buy" rating and others maintaining or lowering price targets. The stock was up 5.62% in the 30 days leading up to October 28, 2025.

CryoPort, Inc. experiences demand seasonality, with historical data indicating patterns in monthly returns. October has historically shown a chance of being a "green month" for CYRX. The company's positioning in the life sciences industry is anticipated to drive steady commercial revenue and clinical trial activity, although there has been a noted slowdown in demand for MVE freezers.

CryoPort, Inc. is a global leader providing temperature-controlled supply chain solutions for the life sciences industry, operating in the Air Freight & Logistics sector and serving the biopharma/pharma, animal health, and reproductive medicine markets. The company's offerings include Life Sciences Services and Life Sciences Products, such as advanced temperature-controlled packaging, informatics, specialized bio-logistics services, bio-storage, bio-services, and cryogenic systems. Cryoport is also the world's largest manufacturer of cryogenic systems.

CryoPort, Inc. has a significant global presence across the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), with the majority of its revenue generated from the Americas. The company is expanding its global infrastructure, including a new Global Supply Chain Center in Paris, France, and plans for another in Santa Ana. As of June 30, 2025, Cryoport supported 556 clinical trials in the Americas, 124 in EMEA, and 48 in APAC.

In the past year, Cryoport has received positive recognition, including the "Marketing Team of the Year" award from Life Science Sales and Marketing (LSSM) and the Simon Ellison Supply Chain Innovation Award for Cryoport Systems for the second consecutive year. There is no readily available information indicating any significant negative events that have affected CryoPort, Inc.'s brand reputation.

CryoPort, Inc. has significant institutional ownership, with 330 institutional owners and shareholders holding a total of 53,483,483 shares, representing more than half of the company. Major institutional owners include Cadian Capital Management, Lp, Morgan Stanley, BlackRock, Inc., Brown Capital Management Llc, Vanguard Group Inc, Fred Alger Management, Llc, Millennium Management Llc, Thematics Asset Management, Assenagon Asset Management S.A., VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, Bank of America Corp DE, Canada Pension Plan Investment Board, The Manufacturers Life Insurance Company, Goldman Sachs Group Inc., State Street Corp., and Silvercrest Asset Management Group, Inc. The company's CEO, Jerrell Shelton, directly holds 1.1% of the total shares outstanding.